Sabinsa Successfully Protects its Curcumin C3 Reduct® Technology

July 10, 2017


Sabinsa Corporation manufactures and markets phytonutrients, Ayurvedic herbal extracts and specialty fine chemicals for nutritional, pharmaceutical and food industries. Sabinsa has carved a niche for itself by its extensive research support for its customers and products, and the scientific credentials of its key technical staff. Founded in 1988 by Muhammed Majeed, Ph.D., Sabinsa is a company dedicated to the principles of tradition, innovation and research. Sabinsa's efforts have begun to earn the company vast recognition, in addition to growing sales.

East Windsor, NJ (July 10, 2017) – Sabinsa Corporation announced today that it has successfully concluded its Patent Infringement lawsuit against Aegle Bios, Inc. A Final Consent Judgment was filed in the United States District Court in New Jersey on June 23, 2017..

On June 8, 2016, Sabinsa filed suit against Aegle for willful infringement of the Curcumin Patent No. 6,653,327. The ’327 Patent protects Sabinsa’s methods and formulations for Tetrahydrocurcuminoids (THCs).

The Final Consent Judgment stipulates that the ’327 Patent was valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa continues to litigate the amount owed for willful infringement of the ’327 patent by Olive Lifesciences Private Limited after obtaining final judgments against Chemill Inc. and Nachurel Ingredients LLC.

"As an pioneer in the industry, Sabinsa has researched and developed many innovative and successful products used by the nutritional supplement industry, but unfortunately that success has made us a target for IP theft," said Sabinsa founder Dr. Muhammed Majeed. "Out of necessity, Sabinsa has earned a reputation for strong enforcement of our intellectual property rights, and will continue to pursue all available legal remedies to protect those rights when necessary."

"We are very proud of our partnership with Sabinsa to make sure that its patents are enforced and respected in the industry, especially given the investment the company has made in creating and protecting its intellectual property rights," added James H. Hulme, Sabinsa’s patent counsel. "Sabinsa can now claim a string of patent victories after this latest judgment," Mr. Hulme said.

Sabinsa, which has pioneered the introduction of several herbal extracts in the US market, is an application-oriented manufacturing and marketing company which manufacturers herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical, cosmeceutical, and food products.  Sabinsa distinguishes itself with its extensive research support for its customers and products, and the scientific credentials of its key technical staff.

Curcumin C3 Reduct® is a Registered Trademark and Patented product of Sabinsa Corp., and is protected under U.S. Patent No. 6,653,327, and International Patents and Patents Pending.

About Sabinsa Corporation

Sabinsa Logo Since 1988

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 29 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher. For more information, visit www.sabinsa.com.